This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
by Zacks Equity Research
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
by Zacks Equity Research
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
by Zacks Equity Research
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi
by Zacks Equity Research
The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
by Zacks Equity Research
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
by Zacks Equity Research
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Wall Street Analysts Predict a 28.98% Upside in Harmony Biosciences (HRMY): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HRMY vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. RGEN: Which Stock Is the Better Value Option?
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
by Zacks Equity Research
The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma. A decision is due on May 26, 2025.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
by Zacks Equity Research
Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
by Zacks Equity Research
The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
Zacks.com featured highlights include Harmony Biosciences, Ingevity, Gulfport Energy and Pitney Bowes
by Zacks Equity Research
Harmony Biosciences, Ingevity, Gulfport Energy and Pitney Bowes have been highlighted in this Screen of The Week article.
4 High Earnings Yield Value Stocks to Buy as Trump Resumes Presidency
by Rimmi Singhi
Unlock your portfolio value with high earnings yield value stocks like HRMY, NGVT, GPOR and PBI.
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Harmony Biosciences (HRMY) Might be Well Poised for a Surge
by Zacks Equity Research
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
How Much Upside is Left in Harmony Biosciences (HRMY)? Wall Street Analysts Think 39.48%
by Zacks Equity Research
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 39.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HRMY or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Are Investors Undervaluing Genmab (GMAB) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.